What makes a good drug target?

Drug Discovery Today

Volumn 16, Issue 23-24, 2011, Pages 1037-1043

  Gashaw, Isabella ^a   Ellinghaus, Peter ^b   Sommer, Anette ^a   Asadullah, Khusru ^a  

^a Bayer HealthCare   (Germany)

^b Global Drug Discovery Target Discovery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL FACTOR; ENZYME ACTIVATOR; ENZYME INHIBITOR; NUCLEIC ACID; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR INHIBITOR; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 82255175640     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.09.007     Document Type: Review

References (50)

1. J. Arrowsmith Trial watch: phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328 329
2. J. Arrowsmith Trial watch: phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
3. A.I. Graul, and E. Cruces The year's new drugs & biologics, 2010 Drugs Today (Barc.) 47 2011 27 51
4. M. Lessl Crowd sourcing in drug discovery Nat. Rev. Drug Discov. 10 2011 241 242
5. M. Lessl Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs Drug Discov. Today 16 2011 288 292
6. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
7. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996 (Pubitemid 44835126)
8. T.M. Bakheet, and A.J. Doig Properties and identification of human protein drug targets Bioinformatics 25 2009 451 457
9. P. Imming Drugs, their targets and the nature and number of drug targets Nat. Rev. Drug Discov. 5 2006 821 834 (Pubitemid 44480536)
10. B.L. Davidson, and P.B. McCray Jr Current prospects for RNA interference-based therapies Nat. Rev. Genet. 12 2011 329 340
11. M. Rask-Andersen Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
12. C. Knox DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39 Database issue 2011 1035 1041
13. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009 (Pubitemid 350273630)
14. R.E. Moellering Direct inhibition of the NOTCH transcription factor complex Nature 462 2009 182 188
15. P. Filippakopoulos Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
16. E. Nicodeme Suppression of inflammation by a synthetic histone mimic Nature 468 2010 1119 1123
17. J.A. Zorn, and J.A. Wells Turning enzymes ON with small molecules Nat. Chem. Biol. 6 2010 179 188
18. S. Webb Pharma interest surges in antibody drug conjugates Nat. Biotechnol. 29 2011 297 298
19. B. Hughes Antibody-drug conjugates for cancer: poised to deliver? Nat. Rev. Drug Discov. 9 2010 665 667
20. T.T. Junttila Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res. Treat. 128 2011 347 356
21. S.A. Sieber, and B.F. Cravatt Analytical platforms for activity-based protein profiling - exploiting the versatility of chemistry for functional proteomics Chem. Commun. (Camb.) 22 2006 2311 2319 (Pubitemid 43846363)
22. H. Nakayama Ariadne: a database search engine for identification and chemical analysis of RNA using tandem mass spectrometry data Nucleic Acids Res. 37 2009 47
23. M.C. Henderson High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells Mol. Cancer Res. 9 2011 724 732
24. U. Egner The target discovery process Chembiochem 6 2005 468 479 (Pubitemid 40868134)
25. T. Toyoda, and A. Wada Omic space: coordinate-based integration and analysis of genomic phenomic interactions Bioinformatics 20 2004 1759 1765 (Pubitemid 39162052)
26. S. Ekins Pathway mapping tools for analysis of high content data Methods Mol. Biol. 356 2007 319 350
27. P. Groth Phenoclustering: online mining of cross-species phenotypes Bioinformatics 26 2010 1924 1925
28. P. Groth Mining phenotypes for gene function prediction BMC Bioinformatics 9 2008 136
29. F. Prinz Believe it nor not - how much can we rely on published data? Nat. Rev. Drug Discov. 10 9 2011 712 10.1038/nrd3439-c1
30. A. Wendler, and M. Wehling The translatability of animal models for clinical development: biomarkers and disease models Curr. Opin. Pharmacol. 10 2010 601 606
31. E. Dolgin Animalgesic effects Nat. Med. 16 2010 1237 1240
32. A. von Bonin Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases Exp. Dermatol. 20 2011 41 47
33. U. Egner, and R.C. Hillig A structural biology view of target drugability Expert Opin. Drug Discov. 3 2008 391 401 (Pubitemid 351618766)
34. Z. Gao PDTD: a web-accessible protein database for drug target identification BMC Bioinformatics 9 2008 104
35. S. Henrich Computational approaches to identifying and characterizing protein binding sites for ligand design J. Mol. Recognit. 23 2010 209 219
36. S.M. Wilhelm Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol. Cancer Ther. 7 2008 3129 3140
37. C.H. Takimoto, and A. Awada Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials Cancer Chemother. Pharmacol. 61 2008 535 548
38. A. Muchir Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins Hum. Mol. Genet. 18 2009 241 247
39. K. Lorenz Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling Int. J. Biochem. Cell Biol. 41 2009 2351 2355
40. B.B. Hasinoff, and D. Patel The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro Toxicol. Appl. Pharmacol. 249 2010 132 139
41. J.J. Li Triumph of the Heart: The Story of Statins 2009 Oxford University Press
42. J.A. Tobert Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors Nat. Rev. Drug Discov. 2 2003 517 526 (Pubitemid 37361744)
43. C.A. Lipinski The anti-intellectual effects of intellectual property Curr. Opin. Chem. Biol. 10 2006 380 383 (Pubitemid 44097010)
44. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
45. R. Fukushima Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine Toxicol. Sci. 108 2009 419 426
46. S.B. Ng Exome sequencing identifies the cause of a mendelian disorder Nat. Genet. 42 2010 30 35
47. V. Gailus-Durner Systemic first-line phenotyping Methods Mol. Biol. 530 2009 463 509
48. F. Zhu Update of TTD: therapeutic target database Nucleic Acids Res. 38 Database issue 2010 787 791
49. M. Ohtawa Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans Br. J. Clin. Pharmacol. 35 1993 290 297 (Pubitemid 23074055)
50. K. Asadullah, and F. Kramer Biomarkers for intensive care medicine patients: the (stony) path into a bright future? Biomarkers 16 Suppl. 1 2011 1 4